



Kaplan-Meier survival analysis of Vedolizumab treatment persistence up to 54 weeks according to week 14 VTL (dotted line: VTL > 16 µg/ml, continuous line: VTL ≤ 16 µg/ml)

a) for UC patients HR = 2.18, 95% CI 1.01-5.9, Logrank test: p = 0.047

b) for CD patients HR 2.39, 95% CI 0.63-13.9, Logrank test: p = 0.16


Supplementary Figure 2



a) ROC curve analysis of week 6 VTL and clinical remission at week 14, cut-off  $> 29.9 \mu\text{g/ml}$ , sensitivity 66.7%, specificity 66.7%, AUROC 0.641, 95%CI 0.538-0.735,  $p = 0.02$ )


b) ROC curve analysis of week 6 VTL and clinical remission at week 22 cut-off  $> 29.3 \mu\text{g/ml}$ , sensitivity 63.9%, specificity 67.9%, AUROC 0.652, 95%CI 0.556--0.749,  $p = 0.01$

Supplementary Figure 3




a) ROC curve analysis of week 14 VTL and clinical remission at week 14, cut-off > 16.4 µg/ml, sensitivity 96.9%, specificity 55%, AUROC 0.741, 95%CI 0.639-0.827, p=0.0001 b) ROC curve analysis of week 14 VTL and clinical remission at week 14 plus normal CRP, cut-off > 17.4 µg/ml, sensitivity 94.1%, specificity 53.3%, AUROC 0.712, 95%CI 0.608-0.802, p=0.0049 c) ROC curve analysis of week 14 VTL and clinical remission at week 22, cut-off > 16.4 µg/ml, sensitivity 97.1%, specificity 60%, AUROC 0.772, 95%CI 0.668-0.857, p=0.0001d) ROC curve analysis of week 14 VTL and clinical remission at week 22 plus normal CRP, cut-off > 16.4 µg/ml, sensitivity 100%, specificity 53.6%, AUROC=0.708, 95%CI 0.594-0.805, p= 0.0027


## Supplementary Figure 4



a)




b)




c)

- a) ROC curve analysis of week 14 VTL and clinical remission at week 54, cut-off  $> 18 \mu\text{g/ml}$ , sensitivity 70.3%, specificity 76.5%, AUROC 0.744, 95%CI 0.608-0.853,  $p=0.0003$
- b) ROC curve analysis of week 14 VTL and clinical remission at week 54 plus normal CRP, cut-off  $> 16.6 \mu\text{g/ml}$ , sensitivity 85%, specificity 65.4%, AUROC 0.690, 95%CI 0.537-0.818,  $p=0.018$
- c) ROC curve analysis of week 14 VTL and mucosal healing, cut-off  $> 16.6 \mu\text{g/ml}$ , sensitivity 80.9%, specificity 72.7%, AUROC=0.773, 95%CI 0.639-0.876,  $p= 0.0001$



a)



b)

a) Rates of clinical remission at week 14 by quartiles (Q) of VTL at Week 6 (quartiles 1+2 vs 3+4,  $p < 0.019$ );

b) Rates of clinical remission at week 22 by quartiles of VTL at Week 6 ( $p = 0.04$ )